AKT1 and neoplasm: However, despite pre-clinical data indicating that rapamycin and its analogs have anti-tumor activity, early clinical trials did not show universal anti-tumor activity, especially for tumors with high levels of PI3K-Akt activity, such as glioblastoma [11], [19] and breast cancers [20].